跳至主要内容
临床试验/NCT02985723
NCT02985723已完成不适用

Prospective Study to Evaluate the Visual Outcome, Cylinder Correction and Patient Satisfaction After Implantation of AT LISA Tri Toric 939MP Intraocular Lenses

Carl Zeiss Meditec AG0 个研究点目标入组 120 人开始时间: 2013年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
120
主要终点
Best distance-corrected visual acuity for intermediate vision after bilateral implantation

研究概览

简要总结

The aim of the present study is to evaluate the postoperative visual acuity for distance, intermediate and near vision as well as the cylinder correction and the patient satisfaction after bilateral implantation of AT LISA tri toric 939MP IOLs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent
  • Man or woman, over 50 years of age
  • Healthy eyes with bilateral cataract requiring surgical treatment for both eyes
  • Bilateral regular corneal astigmatism (confirmed by topography measurement)
  • Only patients requiring intraocular lenses of a power comprised between sphere +0.0 and +28.0 dioptres and between a cylindrical range of +1.0 to +4.0D in both eyes will be able to participate in the trial.
  • Biometry measurement/cataract density compatible with the IOLMaster evaluation
  • Bilateral uncomplicated cataract surgery and implantation into capsular bag by injector
  • Assured follow-up examinations

排除标准

  • Patients unable to meet the limitations of the protocol or likely of non cooperation during the trial,
  • Patients whose freedom is impaired by administrative or legal order,
  • Monophtalmic patient.
  • Previous ocular surgery, including corneal/refractive surgery,
  • Chronic or recurrent uveitis,
  • Acute ocular disease or external/internal infection,
  • Any kind of macular degeneration and impairment of retina (clinical diagnosis/OCT examination)
  • Diabetes with retinal changes,
  • Pseudoexfoliation syndrome
  • Pathologic myosis
  • Irregular astigmatism, especially keratoconus,
  • Endothelial corneal dystrophy
  • Glaucoma or IOP higher than 21mmHg under ocular hypertension treatment
  • Pseudophakia
  • Cornea guttata; keratoplasty
  • Amotio operation; anamnesis with vitreous surgery
  • Amblyopia
  • Intraocular tumours; endotamponade
  • Phlogistic intraocular processes or other pre-existing processes that permanently limit the best corrected visual acuity to > 0.3 logMAR
  • Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient
  • Pupil diameter over 6 mm in mesopic condition
  • Corneal opacity

研究组 & 干预措施

939MP

Experimental

AT LISA tri toric 939MP intraocular lens

干预措施: AT LISA tri toric 939MP (Device)

结局指标

主要结局

Best distance-corrected visual acuity for intermediate vision after bilateral implantation

时间窗: 12 months after surgery

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验